VRXA — Veraxa Biotech Holding AG
Chart, dilution, float and news for VRXA in the TickerWise workspace.
Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company was founded in 2021 and is based in Heidelberg, Germany.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: DE
- Exchange: NASDAQ
- Employees: 8
- Website: https://www.veraxa.com
Latest SEC filings for VRXA
Latest VRXA news
- VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress Read article
- VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy Read article
- Micro-Cap Stock Veraxa Biotech Is Down 96% This Year. Can Next-Gen Drug Testing Save It? Read article
Educational tool only — not investment advice.